Based on the high frequency of TMPRSS2:ERG fusions and the potentially high impact on prostate cells by rendering ERG dependent genes androgen regulated, attempts were made to molecularly classify prostate cancer as “fusion-type” and “non fusion-type”. This evidence concerns the gene ERG and prostate cancer.